icovamenib
icovamenib: developed by 1 company · 2 clinical trials tracked.
icovamenib evidence translation
What we can confirm
2 tracked trials
What it means
What to watch
Prepared research question
How could icovamenib → BMEA affect its developer, and what evidence supports the link?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Biomea Fusion, Inc. (BMEA) Type 2 Diabetes | Phase 2 |
Clinical Trials (2)
Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Not Achieving Glycemic Targets Despite GLP-1-Based Therapy
Primary endpoint: To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control
A Phase 2, Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants With Type 2 Diabetes Who Are Not Achieving Glycemic Targets Despite Antihyperglycemic Medications
Primary endpoint: To demonstrate that icovamenib 100 mg once daily for 12 weeks is superior to placebo for glycemic control
Frequently asked questions
Who is developing icovamenib?
icovamenib is being developed by Biomea Fusion, Inc..
How many clinical trials involve icovamenib?
BioSniper tracks 2 clinical trials involving icovamenib.